Sarepta Therapeutics (SRPT) Q4 2024 earnings summary

Executive summary

• Achieved all strategic and multi-year objectives in 2024, including the successful launch and broad label approval of ELEVIDYS, sustainable profitability, and cash flow positivity.

• ELEVIDYS received the broadest possible label, enabling treatment for most Duchenne patients, and drove the most successful gene therapy launch to date.

• Attained first full year of GAAP and non-GAAP profitability, with disciplined expense management and robust revenue growth.

• Expanded pipeline through Arrowhead collaboration, adding siRNA programs across multiple indications.

• Closed $600M revolving credit facility and announced $500M share repurchase program.

Financial highlights

• Q4 2024 net product revenue was $638.2M, up 75% year-over-year, exceeding guidance by over $60M.

• Full-year 2024 net product revenue reached $1.788B, up 56% year-over-year, surpassing guidance by over $100M.

• Q4 GAAP net income was $159M ($1.65 per basic share); non-GAAP net income was $206M ($1.90 per diluted share).

• Full-year 2024 GAAP net income was $235.2M; non-GAAP net income was $397.9M.

• Ended 2024 with $1.5B in cash and equivalents; secured a $600M revolving credit facility.

Outlook and guidance

• 2025 net product revenue guidance is $2.9B–$3.1B, representing 68–70% growth over 2024; over two-thirds expected from ELEVIDYS.

• ELEVIDYS projected to grow over 160% year-over-year in 2025.

• Combined 2025 non-GAAP R&D and SG&A expenses expected to be $1.2B–$1.3B, mainly due to Arrowhead programs.

• Sequential quarter-over-quarter growth expected throughout 2025.

• Anticipates continued positive cash flow in 2025 and beyond.